EUVIMEDEUVIMED entdecken
Multizentrische StudieMetaanalyseKohortenstudie

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study

Sarah M Baxter, Lars Christian Lund, Jacob H Andersen, Thomas H Brix, Laszlo Hegedüs, Miyuki Hsing-Chun Hsieh, Chris Tzu-Ting Su, Michael Chun-Yuan Cheng, Zoe Chi-Jui Chang, Edward Chia-Cheng Lai, Swaleh Hussain, Cherry Chu und 15 weitere

Thyroid® · 2025-01 · 35 (1) · 69-78

DOI: 10.1089/thy.2024.0387 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thyroid®, online erschienen am 16.01.2025. Verfasst von Sarah M Baxter und 26 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Concerns have been raised that glucagon-like peptide 1 receptor agonists (GLP1-RAs) may increase the risk of thyroid cancer, but evidence remains conflicting. We therefore investigated if GLP1-RA use, compared with use of dipeptidyl peptidase-4 inhibitors (DPP-4is), was associated with thyroid cancer risk in patients with type 2 diabetes.

Methods

This multisite cohort study with subsequent meta-analysis included six population-based databases from Canada (Ontario), Denmark, Norway, South Korea, Sweden, and Taiwan. Study populations comprised patients with type 2 diabetes between 2007 and 2023. Cox regression models estimated hazard ratios (HR) and 95% confidence intervals (CIs) for thyroid cancer among GLP1-RA users compared with DPP-4is. Models were weighted using standardized mortality ratio weights generated from time-specific propensity scores. Site-specific HRs were pooled using a fixed-effects model.

Results

We identified 98,147 users of GLP1-RA and 2,488,303 users of DPP-4i, with the median follow-up among users of GLP1-RA ranging from 1.8 to 3.0 years. Overall, use of GLP1-RA relative to use of DPP-4i was not associated with an increased risk of thyroid cancer (pooled weighted HR 0.81, CI 0.59–1.12). Similarly, we observed no increased risk in thyroid cancer with increasing cumulative dose of GLP1-RA among GLP1-RA ever-users. Subgroup analysis of types of thyroid cancer was not possible. Results remained consistent across a range of supplementary analyses.

Discussion

In this large multisite study, utilizing data from six population-based databases, we found no evidence that GLP1-RA use is associated with an increased risk of thyroid cancer with follow-up ranging from 1.8 to 3.0 years, providing some reassurance to patients and clinicians about the short-term safety of these drugs. Nevertheless, evidence was insufficient to rule out excess risk with long-term use, due to the short follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsGlucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsHumansFemaleMaleMiddle AgedCohort StudiesAgedAdultRisk Factors

Stichwörter der Autor:innen

active comparatordipeptidyl peptidase-4 inhibitorsglucagon-like peptide 1 receptor agoniststhyroid cancer

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsDipeptidyl-Peptidase IV InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland.
  • Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Department of Endocrinology, Odense University Hospital, Odense, Denmark.
  • Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Population Health Data Center, National Cheng Kung University, Tainan, Taiwan.

Zitieren

APA

Baxter, S. M., Lund, L. C., Andersen, J. H., Brix, T. H., Hegedüs, L., Hsieh, M. H., Su, C. T., Cheng, M. C., Chang, Z. C., Lai, E. C., Hussain, S., Chu, C., Gomes, T., Antoniou, T., Eskander, A., Bouck, Z., Tadrous, M., Bea, S., Choi, E. Y., …, & Pottegård, A. (2025). Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study. Thyroid®, 35(1), 69-78. https://doi.org/10.1089/thy.2024.0387

Vancouver

Baxter SM, Lund LC, Andersen JH, Brix TH, Hegedüs L, Hsieh MH, et al. Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study. Thyroid®. 2025;35(1):69-78. doi:10.1089/thy.2024.0387

BibTeX
@article{Baxter2025,
  author = {Baxter, Sarah M and Lund, Lars Christian and Andersen, Jacob H and Brix, Thomas H and Hegedüs, Laszlo and Hsieh, Miyuki Hsing-Chun and Su, Chris Tzu-Ting and Cheng, Michael Chun-Yuan and Chang, Zoe Chi-Jui and Lai, Edward Chia-Cheng and Hussain, Swaleh and Chu, Cherry and Gomes, Tara and Antoniou, Tony and Eskander, Antoine and Bouck, Zachary and Tadrous, Mina and Bea, Sungho and Choi, Eun-Young and Shin, Ju-Young and Modig, Karin and Talbäck, Mats and Ljung, Rickard and Gulseth, Hanne Løvdal and Karlstad, Øystein and Hicks, Blánaid and Pottegård, Anton},
  title = {Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study},
  journal = {Thyroid®},
  year = {2025},
  volume = {35},
  number = {1},
  pages = {69--78},
  doi = {10.1089/thy.2024.0387}
}
Kostenlos starten →